141MO Pathological response and early survival data according to TNBCtype4 classifier in operable triple-negative breast cancer (TNBC) treated with neoadjuvant carboplatin and docetaxel

Diaz-Guardamino, I. Echavarria; Cobo, Sara López-Tarruella; Monte-Millán, Marı́a del; Álvarez, Enrique; Jerez, Yolanda; Antón, Fernando Moreno; Sáenz, José Ángel García; Massarrah, Tatiana; Ocaña, Inmaculada; Cebollero, M.; Garcia, A.I. Ballesteros; Sarmiento, U. Bohn; Gómez, Henry Leonidas; Fuentes, Hugo; López, Beatriz; Casado, S. Gamez; Bueno, Oscar; Jiménez-Santos, María José; Roche-Molina, M.; Jiménez, M. Martín

doi:10.1016/j.annonc.2022.07.176

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective analysis of the I-SPY2 trial also showed that FOXC1 and Ki67-based biomarkers could perfectly predict the poor response to an immune checkpoint inhibitor-based NAC regimen using durvalumab in patients with primary TNBC 29 . The BLIS subtype showed downregulation of immune-regulating and cytokine pathways and had the worst outcome 7,10 . However, the BLIS subtype has high chromosomal instability and constitutes 65% of TNBC with homologous recombination deficiency, a predictive biomarker for response to DNA-damaging agents or poly (ADP-ribose) polymerase (PARP) inhibitors 9 .…”

Section: Discussionmentioning

confidence: 99%

“…29 The BLIS subtype showed downregulation of immune-regulating and cytokine pathways and had the worst outcome. 7,10 However, the BLIS subtype has high chromosomal instability and constitutes 65% of TNBC with homologous recombination deficiency, a predictive biomarker for response to DNA-damaging agents or poly (ADP-ribose) polymerase (PARP) inhibitors. 9 Furthermore, the BLIS subtype had a higher vascular endothelial growth factor signature score than the other subtypes, suggesting that anti-angiogenesis therapy might be a therapy of choice for patients with the BLIS subtype.…”

Section: Discussionmentioning

confidence: 99%

“…The 4-group classification is a strong predictor of response to NAC 6 . However, Echavarria 7 reported that the 4-group classification was not good at predicting long-term survival. Burstein et al 8 proposed an alternative 4-subtype classification of TNBC, which included LAR, MES, basal-like immune suppressed (BLIS), and basal-like immune-activated.…”

mentioning

confidence: 96%

See 2 more Smart Citations

Prognostic Value of Immunohistochemistry-based Subtyping Before and After Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer

Wu,

Chen,

Lin

et al. 2023

American Journal of Surgical Pathology

View full text Add to dashboard Cite

To assess the predictive and prognostic value of a subtyping method based on immunohistochemistry in patients with triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC). This study included patients with TNBC treated with anthracycline- and taxane-based NAC and curative surgery. Immunohistochemical (IHC) subtyping was performed using core needle biopsy specimens before NAC (pre-NAC) and residual tumors after NAC (post-NAC). Logistic regression was performed to identify predictive biomarkers of pathological complete response (pCR). Invasive disease-free survival (iDFS), distant disease-free survival (DDFS), and overall survival (OS) were assessed using the log-rank test and Cox proportional hazards regression. A total of 230 patients were followed up for a median of 59 months. Clinical lymph node status and the pre-NAC subtype were independent predictors of pCR (P=0.006 and 0.005, respectively). The pre-NAC subtype was an independent prognostic factor for long-term survival (iDFS: P < 0.001, DDFS: P=0.010, and OS: P=0.044). Among patients with residual disease (RD) after NAC, approximately 45% of tumors changed their IHC subtype. Furthermore, the post-NAC subtype, but not the pre-NAC subtype, was strongly associated with the survival of patients with RD (iDFS: P < 0.001, DDFS: P=0.005, and OS: P=0.006). The IHC subtype predicted response to NAC and long-term survival in patients with early TNBC. In patients with RD, almost 45% of the tumors changed subtype after NAC. The IHC subtype should be considered when planning additional therapies pre- and post-NAC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Value of Immunohistochemistry-based Subtyping Before and After Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer

Wu,

Chen,

Lin

et al. 2023

American Journal of Surgical Pathology

View full text Add to dashboard Cite

show abstract

“…Unlike advanced or metastatic TNBC [ 40 ], PD-L1 expression was not associated with an improved pCR rate or EFS in the KEYNOTE-522 trial. Other immune-related markers, such as tumor-infiltrating lymphocytes (TIL), are currently being investigated [ 48 , 49 ], and follow-up of these results is needed. Second, the backbone chemotherapy regimen of the KEYNOTE-522 trial consisted of three weekly paclitaxel–carboplatin cycles followed by anthracycline and cyclophosphamide.…”

Section: Introductionmentioning

confidence: 99%

Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)

Lee

2023

JCM

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and is characterized by an aggressive nature and a high rate of recurrence despite neoadjuvant and adjuvant chemotherapy. Although novel agents are constantly being introduced for the treatment of breast cancer, conventional cytotoxic chemotherapy based on anthracyclines and taxanes is the mainstay treatment option for TNBC. Based on CTNeoBC pooled analysis data, the achievement of pathologic CR (pCR) in TNBC is directly linked to improved survival outcomes. Therefore, the treatment paradigm for early TNBC has shifted to neoadjuvant treatment, and the escalation of neoadjuvant chemotherapy to improve the pCR rate and the addition of post-neoadjuvant chemotherapy to control the residual disease have been investigated. In this article, we review the current treatment landscape for early TNBC, from standard cytotoxic chemotherapy to recent data on immune checkpoint inhibitors, capecitabine, and olaparib.

show abstract

Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review

Ende

Nguyen

Jager

et al. 2023

IJMS

View full text Add to dashboard Cite

Around 40–50% of all triple-negative breast cancer (TNBC) patients achieve a pathological complete response (pCR) after treatment with neoadjuvant chemotherapy (NAC). The identification of biomarkers predicting the response to NAC could be helpful for personalized treatment. This systematic review provides an overview of putative biomarkers at baseline that are predictive for a pCR following NAC. Embase, Medline and Web of Science were searched for articles published between January 2010 and August 2022. The articles had to meet the following criteria: patients with primary invasive TNBC without distant metastases and patients must have received NAC. In total, 2045 articles were screened by two reviewers resulting in the inclusion of 92 articles. Overall, the most frequently reported biomarkers associated with a pCR were a high expression of Ki-67, an expression of PD-L1 and the abundance of tumor-infiltrating lymphocytes, particularly CD8+ T cells, and corresponding immune gene signatures. In addition, our review reveals proteomic, genomic and transcriptomic markers that relate to cancer cells, the tumor microenvironment and the peripheral blood, which also affect chemo-sensitivity. We conclude that a prediction model based on a combination of tumor and immune markers is likely to better stratify TNBC patients with respect to NAC response.

show abstract

141MO Pathological response and early survival data according to TNBCtype4 classifier in operable triple-negative breast cancer (TNBC) treated with neoadjuvant carboplatin and docetaxel

Cited by 3 publications

References 0 publications

Prognostic Value of Immunohistochemistry-based Subtyping Before and After Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer

Prognostic Value of Immunohistochemistry-based Subtyping Before and After Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer

Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)

Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review

Contact Info

Product

Resources

About